Physician profile
Louis E Verstringhe
NPI 1043429046
$4,493.95
in general payments reported to CMS, 2019-2025
26 companies · $938 in 2025
The $938 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $514 · 2021: $692 · 2022: $675 · 2023: $445 · 2024: $742 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.81 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Alcon Vision LLC | $652.32 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Sun Pharmaceutical Industries INC. | $528.76 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $405.93 | 2019-2021 | |
| Oyster Point Pharma, INC. | $325.80 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $235.58 | 2019-2022 | |
| Allergan, INC. | $188.26 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $170.38 | 2022-2024 | Miebo, Lotemax Sm, Zylet |
| Tarsus Pharmaceuticals, INC. | $141.19 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $130.07 | 2019-2021 | |
| Rxsight INC | $116.46 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Kala Pharmaceuticals, INC. | $85.85 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $81.57 | 2019-2021 | |
| Astellas Pharma US INC | $54.96 | 2023-2024 | Izervay |
| Mallinckrodt Hospital Products INC. | $51.35 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.52 | 2025 | Tepezza |
| Biotissue Holdings INC. | $40.94 | 2019-2025 | |
| Ocular Therapeutix, INC. | $33.31 | 2021 | |
| Horizon Therapeutics Plc | $28.07 | 2023 | Tepezza |
| Mallinckrodt Enterprises LLC | $21.65 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $20.44 | 2021 | |
| Harrow Eye, LLC | $19.74 | 2024 | |
| Celularity INC. | $19.72 | 2021 | |
| Akorn, INC. | $12.73 | 2019 | |
| Omeros Corporation | $11.87 | 2019 | |
| Alimera Sciences, INC. | $5.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Verstringhe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.